Physician profile
Martha E Sheils
NPI 1619935798
$3,902.44
in general payments reported to CMS, 2019-2025
31 companies · $1,092 in 2025
The $1,092 reported for 2025 was more than what 87% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $435 · 2020: $63.87 · 2021: $95.33 · 2022: $643 · 2023: $360 · 2024: $1,214 · 2025: $1,092.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,666.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,665.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $545.28 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $478.99 | 2021-2025 | Vraylar, Ubrelvy |
| Amgen INC. | $442.24 | 2019-2025 | Otezla, Repatha, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $398.73 | 2022-2025 | Jardiance, Tradjenta |
| Lilly USA, LLC | $379.61 | 2019-2025 | Mounjaro, Zepbound, Emgality |
| Astrazeneca Pharmaceuticals LP | $337.72 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Pfizer INC. | $236.93 | 2021-2025 | |
| Medtronic, INC. | $167.29 | 2022-2024 | Reveal Linq, Intellis Adaptivestim |
| Glaxosmithkline, LLC. | $135.08 | 2022-2025 | Shingrix, Trelegy Ellipta, Arexvy |
| Exact Sciences Corporation | $101.71 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Astellas Pharma US INC | $77.84 | 2019-2024 | Veozah |
| Merck Sharp & Dohme LLC | $75.82 | 2019-2025 | Gardasil 9, Capvaxive |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $57.69 | 2019-2024 | Xifaxan |
| Grt US Holding, INC. | $53.75 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $40.97 | 2019-2022 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shield Therapeutics INC | $38.13 | 2023-2024 | Accrufer |
| Otsuka America Pharmaceutical, INC. | $35.83 | 2024 | Rexulti |
| Radius Health, INC. | $34.99 | 2019 | |
| Janssen Pharmaceuticals, INC | $33.82 | 2019 | |
| Abbott Laboratories | $30.93 | 2019-2021 | |
| Scilex Pharmaceuticals INC. | $25.43 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $23.09 | 2022 | |
| Lucid Diagnostics INC. | $22.14 | 2025 | |
| Alk-Abello, INC | $20.59 | 2025 | Odactra, Ragwitek, Grastek |
| Almatica Pharma LLC | $17.84 | 2022 | |
| Azurity Pharmaceuticals, INC. | $17.11 | 2025 | |
| Baxter Healthcare | $16.11 | 2020 | |
| Nevro Corp. | $15.70 | 2024 | Senza |
| Eisai INC. | $15.47 | 2021 | |
| Corcept Therapeutics | $14.21 | 2025 | Korlym |
| Allergan, INC. | $11.40 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Martha Sheils listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.